CRI enters the week with a striking tension: the stock has surged 23% over the past month, shorts have been steadily rebuilding positions, and the Street just upgraded the name — yet the consensus remains a hold and Goldman Sachs still carries a sell.
The analyst story is the most immediate catalyst. Wells Fargo's Ike Boruchow lifted CRI to Equal-Weight from Underweight this morning, raising his target from $30 to $42 — a 40% target revision that signals a meaningful shift in conviction from one of the more prominent bears on the name. That move brings the consensus price target to roughly $42.67, almost exactly in line with the current price of $41.10. The Street is neither bullish nor cautious in aggregate: four holds, no sells in the consensus count — but Goldman Sachs remains an outlier, maintaining a Sell with a $29 target set in January. UBS has nudged its Neutral target up twice this year, most recently to $41 in May, reflecting incremental confidence without enthusiasm. Citi carries the only Buy on the board with a $50 target from January, though that was set before the stock had clawed back this much ground.
Short interest is the counter-narrative worth watching. Bears have been quietly adding. Short interest has climbed 24% over the past month to 9.2% of the free float, reaching its highest level in the snapshot window. The weekly pace has accelerated: up 6.7% in the past week alone, with most of that accumulation happening after the stock's post-earnings gap higher in May. That's a meaningful position — roughly 3.35 million shares short, with a days-to-cover of 3.85 per FINRA's most recent fortnightly data. The build looks deliberate, not mechanical. Someone is fading the rally.
The borrow market, however, tells a very different story from the positioning. Availability is exceptionally loose — roughly 1,886% of short interest is currently available to borrow, meaning there are nearly nineteen shares sitting in the lending pool for every one already lent out. That figure has actually tightened slightly from above 2,000% earlier in June, but it remains far from any squeeze-risk territory; the 52-week low availability reading was 165%, which itself was comfortable. Cost to borrow is running at just 0.39%, down 22% over the past month, its lowest level in the snapshot. The borrow market is simply not pricing any stress. Options positioning has ticked slightly more cautious — the put/call ratio is at 0.32, a touch above its 20-day average of 0.30 — but the z-score of 1.2 falls well short of alarm territory. Positioning looks watched but not crowded.
Among apparel peers, CRI's week — up 3.3% — looks modest. VFC gained 4.1% and RL added 4.0% on the week, while COLM slipped 0.5%. CRI is neither leading nor lagging badly, but the stock's 23% one-month run makes the relative underperformance this week easier to understand — some rotation back into names that hadn't already moved as far. The valuation after the rally is not stretched by headline multiples: the stock trades at roughly 12x trailing earnings and 8.5x EV/EBITDA, both of which have expanded 13-15% over the past month. The dividend score ranks in the 91st percentile of the universe, though the dividend history in ORTEX data is stale — investors should verify the current payout status independently.
Insider activity adds a mild caution flag. The CEO sold nearly 11,000 shares at $35.91 in early April, and the CFO has sold across multiple transactions this spring. Net insider activity over the trailing 90 days shows about 34,000 shares net sold. None of the individual transactions are enormous in dollar terms, but the consistent direction — executive selling into the stock's recovery — is worth noting alongside the short rebuild.
The next scheduled catalyst is Q2 earnings on August 3. The stock gained 7.2% on its most recent print in early May and added another 11% in the five days that followed — so the market rewarded the last beat generously. With the Wells Fargo upgrade now digested, the focus shifts to whether that post-earnings momentum continues to attract fresh buyers or whether the short rebuild at 9% of float and the steady insider selling signal something about what insiders and bears see in the next quarter's numbers.
See the live data behind this article on ORTEX.
Open CRI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
